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Dravet syndrome (DS) is an epileptic syndrome caused by mutations in the Scn1a
gene encoding the α1 subunit of the sodium channel Nav1.1, which is associated
with febrile seizures that progress to severe tonic-clonic seizures and associated
comorbidities. Treatment with cannabidiol has been approved to reduce seizures in
DS, but it may also be active against these comorbidities. The aim of this study
was to validate a new mouse model of DS having lower mortality than previous
models, which may serve to further evaluate therapies for the long-term comorbidities.
This new model consists of heterozygous conditional knock-in mice carrying a
missense mutation (A1783V) in Scn1a gene expressed exclusively in neurons of
the CNS (Syn-Cre/Scn1aWT/A1783V). These mice have been used here to determine
the extent and persistence of the behavioral deterioration in different postnatal days
(PND), as well as to investigate the alterations that the disease produces in the
endocannabinoid system and the contribution of inflammatory events and impaired
neurogenesis in the pathology. Syn-Cre/Scn1aWT/A1783V mice showed a strong reduction
in hindlimb grasp reflex at PND10, whereas at PND25, they presented spontaneous
convulsions and a greater susceptibility to pentylenetetrazole-induced seizures, marked
hyperactivity, deficient spatial working memory, lower levels of anxiety, and altered
social interaction behavior. These differences disappeared at PND40 and PND60,
except the changes in social interaction and anxiety. The analysis of CNS structures
associated with these behavioral alterations revealed an elevated glial reactivity in
the prefrontal cortex and the dentate gyrus. This was associated in the dentate
gyrus with a greater cell proliferation detected with Ki67 immunostaining, whereas
double-labeling analyses identified that proliferating cells were GFAP-positive suggesting
failed neurogenesis but astrocyte proliferation. The analysis of the endocannabinoid
system of Syn-Cre/Scn1aWT/A1783V mice confirmed reductions in CB1 receptors
and MAGL and FAAH enzymes, mainly in the cerebellum but also in other areas,
whereas CB2 receptors became upregulated in the hippocampus. In conclusion,
Syn-Cre/Scn1aWT/A1783V mice showed seizuring susceptibility and several comorbidities
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(hyperactivity, memory impairment, less anxiety, and altered social behavior), which
exhibited a pattern of age expression similar to DS patients. Syn-Cre/Scn1aWT/A1783V
mice also exhibited greater glial reactivity and a reactive response in the neurogenic niche,
and regional changes in the status of the endocannabinoid signaling, events that could
contribute in behavioral impairment.
Keywords: Dravet syndrome, infantile epileptic refractory syndromes, Syn-Cre/Scn1aWT/A1783V mice,
neuropathological characterization, cannabinoids, endocannabinoid signaling, inflammation, neurogenesis
INTRODUCTION
Dravet syndrome (DS), also known as severe myoclonic epilepsy
of infancy, was described in 1978 by Dravet (1978). DS is a
rare genetic pediatric epileptic encephalopathy whose incidence
is estimated around 1:20,000 subjects, representing 1.4% of
children with epilepsy (Skluzacek et al., 2011). DS typically
presents around 5 to 8 months of age with febrile seizures that
progress to severe partial or generalized tonic-clonic seizures,
myoclonic seizures, atypical absences, and focal seizures, as well
as episodes of status epilepticus (in 80% of cases during the first
year of life) (Skluzacek et al., 2011). DS is often accompanied
by important comorbidities such as cognitive impairment and
intellectual disability, behavioral disturbances with hyperactivity,
attention deficits, and sometimes autistic traits, having also a
higher incidence of sudden unexpected death (Skluzacek et al.,
2011; Guerrini, 2012). Seizures tend to become less frequent
during adolescence and, in some cases, disappear in adulthood,
despite long-term cognitive, emotional, speech, and motor
deficits frequently remaining in patients (Darra et al., 2019). In
∼80% of patients, DS is caused by haploinsufficiency derived
from de novo mutations in Scn1a, the gene encoding the α-
subunit of the voltage-gated sodium channel Nav1.1, mutations
that lead to a loss of function in this channel (Bender et al., 2012;
Guerrini, 2012). This loss of function in Nav1.1 causes a marked
reduction in the sodium current and an impairment in the firing
of many types of GABAergic interneurons, in particular the
fast-spiking parvalbumin-positive interneurons, where Nav1.1. is
primarily located (Oakley et al., 2001; Bender et al., 2012). This
results in an imbalance between excitation and inhibition, likely
contributing to hyperexcitability and seizures (Cheah et al., 2012)
and alterations in the normal function of neural networks known
to be critical for the cognitive processes (Bender et al., 2012).
Given the genetic origin of this disease, numerous knock-out,
knock-in, and transgenic models (most of them in mice) have
been developed (Oakley et al., 2001; Yu et al., 2006; Ogiwara
et al., 2007; Tang et al., 2009; Martin et al., 2010; Cheah et al.,
2012; Dutton et al., 2013; Miller et al., 2014; Rubinstein et al.,
2015; Tsai et al., 2015; Griffin et al., 2018), so that they may be
used to better understand the molecular and cellular mechanisms
underlying the physiopathology of DS, as well as to investigate
novel treatments. For example, the use of these models has
primarily served to investigate the mechanism of epileptogenesis
in DS, which is hypothesized, as mentioned above, to be a
reduction in GABA-dependent inhibitory transmission leading
to brain hyperexcitability and seizures (Ogiwara et al., 2007;
Tai et al., 2014). The most common murine models for DS are
based on total or partial deletions of Scn1a gene or expression
of specific human point mutations found in this gene, always
under different promoters and allowing total or conditional
(using Cre-loxP strategies) gene manipulations (Oakley et al.,
2001; Yu et al., 2006; Ogiwara et al., 2007; Tang et al., 2009;
Martin et al., 2010; Cheah et al., 2012; Dutton et al., 2013; Miller
et al., 2014; Rubinstein et al., 2015; Tsai et al., 2015; Griffin
et al., 2018). These models, in general, recapitulate the different
characteristics of this pathology, mainly the seizuring activity,
but with different timings and extents, then serving for different
experimental purposes (reviewed in Griffin et al., 2018). For
example, the models based on homozygous deletion of the Scn1a
gene present premature mortality (before 2 weeks after birth,
Ogiwara et al., 2007), whereas the heterozygous deletion leads
to haploinsufficiency generating spontaneous seizures, delayed
mortality (from 3 to 12 weeks of age having only 20% of long-
term survival), and invalidating comorbidities (Yu et al., 2006).
Models based on the conditional deletion (or expression of
Scn1a mutations) in specific cell populations, for example, in
hippocampal neurons (Stein et al., 2019), forebrain interneurons
(Cheah et al., 2012; Han et al., 2012), or parvalbumin-positive
interneurons (Tatsukawa et al., 2018), have also been developed
and served to investigate the relation of these cell populations
with DS, and more specifically with some comorbidities (e.g.,
hyperactivity, altered anxiety-like behavior, excessive stereotyped
behaviors, deficits in social interaction behavior, spatial learning,
and memory impairment) frequently associated with the disease.
The fact that DS pathogenesis still remains poorly understood
explains the limited therapeutic development for this disease
to date. The antiepileptic drugs used as first-line therapy are
valproate, topiramate, and clobazam, but the response to these
drugs is often inadequate (patients are usually drug-resistant),
and, although it improves when stiripentol is used as an adjuvant
(Frampton, 2019), they have limited efficacy and produce adverse
effects, so there is an urgent need of new therapies for DS
(Bialer et al., 2018; Brigo et al., 2018). Data generated along
the last 6 years suggest that a promising therapy for DS may
be based on the use of certain cannabinoids, e.g., cannabidiol
(CBD) (Franco and Perucca, 2019; Morano et al., 2020), which
not only target the so-called endocannabinoid system but also
other elements outside this signaling system (Gray and Whalley,
2020). This has been demonstrated in a series of clinical
studies conducted in patients affected by DS, Lennox-Gastaut
syndrome, or similar pathologies, using CBD, formulated as
Epidiolex R©, and concentrating on its activity on seizures (Porter
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and Jacobson, 2013; Devinsky et al., 2016, 2018; Nabbout and
Thiele, 2020). These studies demonstrated that CBD was well
tolerated and reduced seizure frequency and intensity in these
patients (Porter and Jacobson, 2013; Devinsky et al., 2016, 2018;
Nabbout and Thiele, 2020), which led to the recent approval of
Epidiolex R© by some regulatory agencies as an anticonvulsant
agent for these treatment-resistant infantile epilepsies1,2, being
currently under investigation for tuberous sclerosis complex
(Hess et al., 2016). However, beyond the anticonvulsant
properties of Epidiolex R©, CBD, given its well-demonstrated
anti-inflammatory, antioxidant, and cytoprotective properties
(Fernández-Ruiz et al., 2013), may also be beneficial against
important comorbidities associated with the disease, such as the
long-term cognitive, motor, emotional, and speech deterioration,
a fact already investigated in a couple of recent studies conducted
in experimental models of DS (Kaplan et al., 2017; Patra et al.,
2020) and also after hippocampal kainate lesions in juvenile
rats (Friedman and Wongvravit, 2018). This possible long-
term efficacy of CBD might be related to a correction of a
possible dysregulation of the endocannabinoid signaling system
[which would contain potential pharmacological targets for CBD
(Fernández-Ruiz et al., 2013)] occurring in the CNS, as has
been found in other neurological disorders (Cristino et al.,
2020). Such dysregulation in the endocannabinoid signaling
was recently proposed also for DS based on studies carried
out in lymphocytes from DS patients (Rubio et al., 2016), but
the evidence is indirect and would need to be confirmed in
animal models of DS. The possibility of a dysregulation in
the endocannabinoid system was not investigated in the two
studies that explored the efficacy of CBD against DS-associated
comorbidities (Kaplan et al., 2017; Patra et al., 2020), so to explore
this possibility has been the final objective of our present study.
These two previous studies (Kaplan et al., 2017; Patra et al.,
2020) were carried out in models of heterozygous deletion of
Scn1a gene, which, as mentioned above, recapitulate DS features
because of the loss of function of DS mutations in this gene.
However, these mice exhibited a high premature mortality (Yu
et al., 2006), which makes difficult, in general, to progress in
the study of novel therapies for the treatment of long-term
comorbidities, and, in the case of cannabinoids, to investigate
the contribution of possible endocannabinoid dysregulations in
the DS pathogenesis and/or in the therapy efficacy. This was
an important consideration for the design of our present study,
which was conducted in a novel murinemodel of DS based on the
expression of the A1783V mutation in the exon 26 of the Scn1a
gene instead on the classic deletion of this gene. A1783V is one of
the most frequent missense mutations described so far (Lossin,
2009) and, overexpressed in animal models, has been found to
be associated with important motor and cognitive disturbances
reminiscent of DS (Ricobaraza et al., 2019), so it may represent
an ideal model for future studies on disease-modifying therapies
in DS, including CBD and other cannabinoids. A similar model




resulted to be an excellent tool for the study of numerous
pathogenic aspects of DS. However, this mouse model also
presented high rates of mortality (>75% at 40 days of age),
which may again limit its use for investigating therapies for long-
term comorbidities. In these DS mice, the A1783V mutation is
expressed in all body cells [using mice with Cre-recombinase
(Cre) under the CMV promoter; see (Ricobaraza et al., 2019)].
Therefore, for our study, we crossed heterozygous conditional
knock-in mice [B6(Cg)-Scn1atm1.1Dsf/J] carrying the missense
A1783Vmutation in Scn1a gene with mice expressing Cre linked
to synapsin-1 promoter [CreB6.Cg-Tg(Syn1-cre)671Jxm/J], then
resulting in the generation of mice with the A1783V mutation
exclusively in CNS neurons (Syn-Cre/Scn1aWT/A1783V) and three
different control mice (Scn1aWT/WT, Syn-Cre/Scn1a WT/WT,
and Scn1a WT/A1783V). Such strategy should elevate mouse
survival, facilitating the study of long-term therapies, as well
as provide information on the specific role played by the
mutant channel in the progression of the disease when expressed
exclusively in CNS neurons. Therefore, the objectives of our
study were first to characterize this new conditional knock-in
mouse model of DS paying emphasis on its survival, its seizure
susceptibility, and its responses in motor, cognitive, anxiety, and
social interaction tests at different postnatal days (PND). Our
second objective was to determine the contribution to these
behavioral disturbances of inflammatory events occurring in
specific CNS areas that control these behavioral processes, as well
as the contribution of alterations in hippocampal neurogenesis
which have been associated with cognitive impairment in
epileptic conditions (Muro-García et al., 2019; Martín-Suárez
et al., 2020). Both objectives were followed by the above-
mentioned attempt to identify the alterations that the disease
produces in the endocannabinoid system, which would contain
the potential targets for any tentative cannabinoid-based therapy.
As mentioned above, the final expectation is that these mice may
be furtherly used to confirm the benefits of an anti-inflammatory
therapy with CBD (or other cannabinoids) against the long-term
deficits found in this disease, using, in this case, a model based on
the conditional expression of A1783V mutation rather than the
models generated by heterozygous deletion of Scn1a gene used in
previous studies (Kaplan et al., 2017; Patra et al., 2020).
MATERIALS AND METHODS
Animals, Genotyping, Experiments, and
Sampling
We used conditional knock-in mutant mice (knock-in mutation
A1783V in Nav1.1 protein) generated by Cre-loxP technology,
in which the Scn1a gene is primarily mutated in neuronal cells.
With this purpose, B6(Cg)-Scn1atm1.1Dsf/J mice (heterozygous
for the transgene, JAX stock #026133) were crossed with Cre-
recombinase linked to synapsin-1 promoter mice (CreB6.Cg-
Tg(Syn1-cre)671Jxm/J; JAX stock #003966), both acquired from
The Jackson Laboratory (Bar Harbor, ME, USA), breedings
which gave rise to offspring in one of the four following
experimental groups: the Syn-Cre/Scn1aWT/A1783V mice, which
bear the A1783V mutation in Nav1.1 protein exclusively in CNS
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TABLE 1 | Sequences of primers used for genotyping by PCR.
Gene Primers
Scn1a F: 5′-TAC TGG GAT CCA CCT CCA CT-3′
R: 5′-TAG CTC CGC AAG AAA CAT CC-3′
Syn-Cre F: 5
′
-CTC AGC GCT GCC TCA GTC T-3′
R: 5′-GCA TCG ACC GGT AAT GCA-3′
neurons, showing the pathological phenotype, and their three
different control mice, Scn1aWT/WT (wild type not expressing
Cre), Syn-Cre/Scn1aWT/WT (wild type expressing Cre), and
Scn1aWT/A1783V (A1783V mutant not expressing Cre), which
show, in general, a normal phenotype. Genotypes were verified
by polymerase chain reaction (PCR) using genomic DNA from
mouse tail biopsies. Genomic DNA was extracted and amplified
using REDExtract-N-Amp Tissue PCR kit (Sigma-Aldrich,
Madrid, Spain) and following manufacturer’s instructions.
Specific pairs of primers used are indicated in Table 1. PCR
products were separated by electrophoresis in 2% agarose gels
and visualized using GelRed. A representative PCR is shown
in Supplementary File 1. During the experiments, mice were
housed in a room with a controlled photoperiod (08:00–20:00
light) and temperature (22 ± 1◦C), and with free access to
food and water. All experiments were conducted according
to the national and European guidelines (RD 53/2013 and
directive 2010/63/EU, respectively), following the principles of
the ARRIVE and 3R guidelines, and were approved by the
Animal Welfare Committee of the Complutense University and
the “Comunidad de Madrid” (ref. PROEX 033/17). All possible
efforts were made to minimize animal pain and discomfort, as
well as reduce the number of experimental subjects.
The study was divided in two experiments. In the first
one, Syn-Cre/Scn1aWT/A1783V mice and their different controls
(Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V) were
analyzed at different PNDs in some behavioral tests (grasp
reflexes, rotarod, computer-aided actimeter, Y-maze, elevated
plus maze, and social interaction). The period investigated
included from PND10 (only grasp reflexes) up to PND60
(all tests). In a second experiment, and given that PND25
was the age at which behavioral impairment was maximal,
we generated Syn-Cre/Scn1aWT/A1783V mice and controls (only
Scn1aWT/WT, given that no differences were found among the
three control groups in the first experiment), which were used at
this age for two purposes. On one hand, we were interested in
analyzing the seizure activity of Syn-Cre/Scn1aWT/A1783V mice
compared with their controls after being both acutely injected
with the proconvulsant agent PTZ. On the other hand, an
additional cohort of Syn-Cre/Scn1aWT/A1783V and Scn1aWT/WT
mice was euthanized by rapid decapitation at PND25 and brains
were rapidly removed and divided into the two hemispheres.
Left hemispheres were fixed for 1 day at 4◦C in fresh 4%
paraformaldehyde prepared in 0.1M phosphate-buffered saline
(PBS), pH 7.4, then cryoprotected by immersion in a 30% sucrose
solution for a further day, and finally stored at −80◦C for
immunohistochemical analysis. Right hemispheres were rapidly
dissected in different brain areas of interest, such as prefrontal
cortex, striatum, hippocampus, and cerebellum, which were
frozen in 2-methylbutane cooled in dry ice and stored at −80◦C
until processing for western blot or qPCR analysis of different
proteins of interest, including endocannabinoid elements.
Behavioral Recording
The behavioral tests were performed to detect possible motor
deficits (limb grasp reflexes, rotarod test, computer-aided
actimeter), cognitive and emotional impairments (Y-maze
and elevated-plus maze tests), and autistic-like traits (social
interaction test) at some representative ages after birth: PND10
(only reflexes), PND25, PND40, and PND60 (all tests). Mice
were transferred to the behavior room and acclimated for 1 h
before testing to prevent that a novel environment can modify
the behavioral response. Tests were carried out in the following
order in two consecutive days: open-field and social interaction
test were performed the day before reaching each age, followed
by Y-maze and elevated plus-maze performed at each specific
age. In behavioral assays, all animals were tested during the light
cycle at the same time of the day (to 9:00 until 12:00 a.m.) in a
room illuminated by a dim lamp (∼50 lux), and each individual
mouse was tested no more than twice per day. In all cases, the
equipment was cleaned with 70% ethanol before and after testing
of each mouse.
Analysis of Limb Grasp Reflexes
Forelimb and hindlimb grasp reflexes were measured as an index
of motor development (Blaney et al., 2013). Mice were held on
their back, and the fore- and hindlimbs were touched with a thin
rod of 1mmdiameter. A score of 1 was assigned if the stimulation
caused the fore- or hindlimb to grasp, whereas a score of 0 was
assigned if no response was reached.
Vibrissae Response
Vibrissae response was measured to record the development of
the tactile sensory system (Blaney et al., 2013). Mice were held
by their tail and approached toward a flat surface. A score of 1
was assigned if mice raised their head to avoid contact with the
flat surface due to vibrissae stimulation, whereas a score of 0 was
assigned if no response was reached.
Computer-Aided Actimeter
Motor activity was analyzed in a computer-aided actimeter
(Actitrack, Panlab, Barcelona, Spain) (Palomo-Garo et al., 2016).
This apparatus consisted of a 45 × 45 cm area, with infrared
beams all around, spaced 2.5 cm, coupled to a computerized
control unit that analyzes the following parameters: (i) distance
run in the actimeter (ambulation); (ii) frequency of vertical
activity (rearing); (iii) resting time; (iv) mean velocity spent in
ambulation; and (v) time spent in fast movements (>5 cm/s).
Animals remained for a period of 40min in the actimeter, and
measurements were recorded during each 10min (first 10min
was used only for animal acclimation).
Rotarod Test
Motor coordination was measured in a LE8200 device (Panlab,
Barcelona, Spain) following a procedure previously described
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(Palomo-Garo et al., 2016). After a period of acclimation and
training (first session: 0 rpm for 10 s; second and third sessions: 4
rpm for 10 s), animals were tested with an acceleration from 4 to
40 rpm over a period of 300 s. Mice were tested for 3 consecutive
trials and the mean of the 3 trials was calculated.
Elevated Plus Maze
Animal anxiety was measured in the elevated plus maze that
consisted of two opposite closed (30 × 5 × 15 cm) and open (30
× 5 cm) arms forming a plus-shaped maze. The structure was
elevated to a height of 40 cm from the floor and all four arms were
connected at right angle at a central area. At the beginning of a
trial, each animal was placed in the intersection of the four arms
(facing an open arm) and were left free to explore the maze for
5min. During this test period, the following behavioral measures
were recorded: (i) number of open and closed arm entries; and
(ii) time spent in the open and closed arms. Closed-arm entries
(counts/5min) were considered indicators of locomotor activity,
whereas open-arm exploration (% time spent in open arms and
% open arm entries) were used as measures of anxiety (Walf and
Frye, 2007).
Y-Maze Test
The Y-maze is a behavioral test used to measure the spatial
working memory in mice based on the capacity of rodents to
explore new environments. The apparatus is a polyvinyl plastic
horizontal maze formed by 3 arms (40 × 12 × 3 cm) placed
at 120◦ angles to each other and designated as A, B, and C.
Each animal was placed in the center of the maze and was
allowed to freely explore the three arms. The sequence (i.e.,
ABCCAB, etc.) and the number of arm entries were recorded
during 8min. The spontaneous alternation performance (SAP),
a score of three consecutive different arm entries (ABC, CAB, or
BCA), was analyzed. Memory impairments are also evaluated by
the frequency of same arm returns (SAR) or alternate arm return
(AAR). The alternation percentage was calculated according to
the equation follows: % alternation= [(number of alternations) /
(total arm entries)]× 100 (Joshi et al., 2014).
Social Interaction Test
This test is frequently used to determine social anxiety. It is
conducted in an open-field arena (45 × 45 cm) in which each
experimental animal was placed together with a novel unfamiliar
congener in an environment and was allowed to freely explore
him. The behavior was recorded for 20min, and the total
time spent by the experimental mouse in nonaggressive social
interactions such as sniffing, following, or grooming the partner,
was monitored (Silverman et al., 2010). Also, the number of
active contacts with the partner was scored.
Analysis of PTZ-Induced Seizuring Activity
Seizuring activity was induced by administration of the
proconvulsant PTZ, following a previous method (Alachkar
et al., 2020). PTZ (Sigma-Aldrich, Madrid, Spain) was freshly
dissolved in sterile saline (0.9% NaCl) to prepare a solution
with a concentration of 10 mg/ml. The test was conducted
on mice at PND25 which where individually placed in glass
boxes and injected with PTZ (50 mg/kg, i.p.) and were then
observed for a 30-min period. During this period, several
behavioral parameters were recorded: (i) latency to myoclonic
jerks, (ii) latency to generalized seizures, and (iii) total duration
of generalized seizures.
Real-Time qRT-PCR Analysis
Total RNA was extracted from prefrontal cortex, striatum,
hippocampus, and cerebellum of right brain hemisphere
samples using SurePrepTM RNA/Protein Purification kit (Fisher
BioReagents, FairLawn, NJ, USA). The total amount of RNA
extracted was quantitated by spectrometry at 260 nm, and its
purity was evaluated by the ratio between the absorbance values
at 260 and 280 nm, whereas its integrity was confirmed in
agarose gels. To prevent genomic DNA contamination, DNA
was removed and single-stranded complementary DNA was
synthesized from 0.2 µg of total RNA using a commercial kit
(Rneasy Mini Quantitect Reverse Transcription, Qiagen, Izasa,
Madrid, Spain). The reaction mixture was kept frozen at −80◦C
until enzymatic amplification. Quantitative real-time PCR
assays were performed using Taq Man Gene Expression Assays
(Applied Biosystems, Foster City, CA, USA) to quantify mRNA
levels for CB1 receptor (ref. Mm00432621_s1), CB2 receptor (ref.
Mm00438286_m1), GPR55 (ref. Mm03978245_m1), FAAH (ref.
Mm00515684_m1), MAGL (ref. Mm00449274_m1), DAGL (ref.
Mm00813830_m1), NAPE-PLD (ref. Mm00724596_m1), TNF-α
(ref. Mm99999068_m1), and BDNF (ref. Mm01334042_m1),
using GAPDH expression (ref. Mm99999915_g1) as an
endogenous control gene for normalization. The PCR assay was
performed using the 7300 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA), and the threshold cycle (Ct)
was calculated by the instrument’s software (7300 Fast System,
Applied Biosystems, Foster City, CA, USA). Expression levels
were calculated using the 2-11Ct method, but, for presentation,
data were transformed to the percentage over the mean obtained
in the wild-type group.
Western Blot
Frozen tissues were homogenized in ice-cold
radioimmunoprecipitation assay (RIPA) buffer for protein
extraction. Homogenates were centrifuged at 10,000 ×
g for 15min at 4◦C. Bio-Rad DC protein assay kit (Bio-
Rad Laboratories, CA, USA) was used to quantify protein
concentration, using bovine serum albumin (BSA) as the
standard protein. Then, 15 µg of protein were boiled for 5min
in Laemmli SDS loading buffer (10% glycerol, 5% SDS, 5%
β-mercaptoethanol, 0.01% bromophenol blue, and 125mM
TRIS-HCl, pH 6.8) and loaded onto a 12% acrylamide gel (TGX
Stain-free Gel FastCast; Bio-Rad Laboratories, CA, USA). After
electrophoresis, proteins were transferred to PVDF membranes
(Immobilon-P, Millipore, MA, USA) using mini Trans-Blot
Electrophoretic transfer cell (Bio-Rad Laboratories, CA, USA).
Membranes were then blocked for 1 h at room temperature with
Tris-buffered saline containing 5% nonfat dried milk and 0.1%
Tween-20 and incubated overnight at 4◦C with the following
primary polyclonal antibodies: anti-FAAH (CAY-101600,
Cayman Chemical, MI, USA) used at 1/1,000, anti-MAGL
(MGL-Rb-Af200, Frontier Institute, Hokkaido, Japan) used at
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1/1,000, anti-CB1 (CB1-Rb-Af380, Frontier Institute, Hokkaido,
Japan) used at 1/500, and anti-CB2 (ab3561, Abcam, Cambridge,
UK) used at 1/200. Membranes were finally incubated with an
ECL horseradish peroxidase-linked whole secondary antibody
(GE Healthcare UK Limited, Buckinghamshire, UK) used at a
1:5,000 dilution for 2 h at room temperature. Reactive bands
were detected by chemiluminescence with the Amersham ECL
Prime Western Blotting Detection Reagent (GE Healthcare UK
Limited, Buckinghamshire, UK). Images were analyzed with
Image Lab software (Bio-Rad Laboratories, CA, USA). Data were
calculated as the ratio between the optical densities of the specific
protein band and the total protein measured in membranes, and
then normalized as percentages over the values of wild-type mice.
Immunofluorescence
Fixed brains were sliced in coronal sections of 30µm thick
(containing prefrontal cortex, striatum, or hippocampus) in a
cryostat (Leica CM3050, Leica, Wetzlar, Germany), collected
on antifreeze solution (glycerol/ethylene glycol/PBS; 2:3:5) and
stored at −20◦C until used. Sections were mounted on gelatin-
coated slides and, once adhered, washed with Tris-buffered
saline at pH 7.5. Then, sections were permeabilized with Tris-
buffered saline containing 0.2% Triton X-100 for 30min, and
unspecificities were blocked with Tris-buffered saline containing
0.1% Triton X-100 and 2% BSA for 1 h. After several washes with
Tris-buffered saline, sections were incubated overnight at 4◦C
with the following primary antibodies: (i) rabbit polyclonal anti-
Iba-1 antibody (Wako Chemicals, Richmond, VA, USA) used
at 1/500 or (ii) rabbit polyclonal anti-GFAP (Dako Cytomation,
Glostrup, Denmark) used at 1/200. Dilutions were carried out
in Tris-buffered saline containing 0.1% Triton X-100 and 2%
BSA. After incubation, sections were washed in Tris-buffered
saline, followed by incubation for 2 h at 37◦C with the secondary
antibody Alexa Fluor 488 donkey anti-rabbit (Life Technologies,
Bleiswijk, The Netherlands) used at 1/200, rendering green
fluorescence. Negative control sections were obtained using the
same protocol with omission of the primary antibody. A Leica
DMRB microscope and a DFC300FX camera (Leica, Wetzlar,
Germany) were used for the observation and photography
of the slides, respectively. Immunostaining was quantified by
measuring the mean density of labeling in the selected area
using the ImageJ software (U.S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012).
For quantification, high-resolution digital microphotographs
were taken with the ×20 objective under the same conditions
of light, brightness, and contrast. Data were normalized over the
values of wild-type mice.
For quantification of cell proliferation in the hippocampal
neurogenic niche, immunostaining was carried out following a
standard procedure: the sections were incubated with blocking
and permeabilization solution containing 0.25% Triton X-
100 and 3% BSA in PBS for 3 h at room temperature,
and then incubated overnight with the primary antibodies
(diluted in the same solution) at 4◦C. After thorough washing
with PBS, the sections were incubated with fluorochrome-
conjugated secondary antibodies diluted in the permeabilization
and blocking solution for 3 h at room temperature. After washing
with PBS, the sections were mounted on slides with Dako
fluorescent mounting medium (Dako, Carpinteria, CA, USA).
The following primary antibodies were used: goat anti-GFAP
(Ab53554, 1/1,000; Abcam, Cambridge, UK) and rabbit anti-
Ki67 (VP-RM04, 1/1,000; Vector Laboratories, Burlingame, CA,
USA). 4′,6-Diamidino-2-phenylindole (DAPI, Sigma-Aldrich), at
1/1,000, was also added to the sections during the incubation
with the secondary antibodies to counterstain cell nuclei.
Quantitative analysis of cell populations was performed by
design-based (assumption free, unbiased) stereology using a
Leica SP8 (Leica, Wetzlar, Germany) laser scanning microscope
and LAS X software. Images were exported as tiffs and adjusted
for brightness, contrast, and background, equally for the entire
image, using the “levels” tools in Adobe Photoshop without
any further modification. All absolute quantifications were
performed at ×40 magnification, capturing frames of known
volume (typically 100w × 100 h × 10 d). Density was then
normalized for the total volume of the dentate gyrus [subgranule
zone (SGZ) + granule cell layer (GCL)] obtained using
DAPI staining. For proportional quantifications (with Ki67),
representative numbers ranging from 50 to 300 cells of interest
were quantified and classified in randomly selected confocal z-
stacks from 30µm below to 30µm above the GCL using a
×63 oil immersion objective. GCL dispersion was calculated by
measuring the thickness of the GCL using DAPI staining for
visualization (distance from the hilus to the molecular layer) in
three different points in each slice. Cell circularity was measured
using the “Circularity” calculation plugin built into ImageJ in
the Analyze/Set Measurements and the Measure and Analyze
Particles commands after importing the images and selecting at
least 50 cells per slice. The command calculates object circularity
using the formula: circularity= 4pi(area/perimeter2).
Statistical Analysis
Data were normally distributed (tested with the Shapiro-Wilk
normality test) and were assessed, as required (see test used in the
legends to figures), by the Student’s t-test or by one- or two-way
(with repeated measures) ANOVA followed by the Bonferroni
test, using GraphPad Prism R© software (version 5.01; GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
Behavioral Data
The first objective (first experiment) of our study was to
demonstrate that our mice exhibited behavioral alterations
reminiscent of DS. To this end, Syn-Cre/Scn1aWT/A1783V mice
and their different controls (Scn1aWT/WT, Syn-Cre/Scn1aWT/WT,
and Scn1aWT/A1783V mice) were subjected to different behavioral
tests at some representative postnatal days (PND10–PND60).
These data are presented in Figures 1–5. In parallel, their
weight was recorded at specific timepoints (Figure 1A) showing
differences by age [F(4, 284) = 28.07, p < 0.0001], but there were
no changes by genotype [F(3, 284) = 0.23, ns] that may be relevant
for the behavioral data.
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FIGURE 1 | Evolution of body weight, rotarod performance, forelimb and hindlimb grasp reflexes, and whisker reflexes in Syn-Cre/Scn1aWT/A1783V mice and their
three control groups (Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice) measured at different postnatal days in the range PND10-PND60. Values are
means ± SEM of 12–21 animals per group. Data were assessed by using two-way ANOVA for repeated measures followed by the Bonferroni test (***p < 0.005 vs.
the other three groups).
Grasp Reflexes
Syn-Cre/Scn1aWT/A1783V mice exhibited a strong reduction in
hindlimb grasp reflex compared with the three control groups
[genotype: F(3, 233) = 5.25, p < 0.005; age: F(3, 233) = 46.45, p
< 0.0001; interaction: F(9, 233) = 5.01, p < 0.0001; Figure 1D].
Such reduction was not seen in frontlimb grasp (Figure 1C)
and whisker reflexes (Figure 1E). This alteration was seen
only at PND10, then disappearing at PND25, PND40, and
PND60, which should be interpreted as a delay in early motor
development of DS newborns.
Motor Coordination and Activity
At PND25, mice were analyzed in the rotarod test to measure
their motor coordination, but no changes among the four
mouse genotypes were detected [genotype: F(3, 172) = 0.08, ns;
Figure 1B]. Such absence of changes was also evident at further
PND40 and PND60 (Figure 1B). Mice were also analyzed at
PND25 in a computer-aided actimeter to record some parameters
reflecting motor activity. Syn-Cre/Scn1aWT/A1783V mice showed
elevated ambulation [genotype: F(3, 185) = 5.10, p < 0.005;
interaction: F(6, 185) = 2.79, p < 0.05; Figure 2A], frequency
of rearing [genotype: F(3, 185) = 3.13, p < 0.05; interaction:
F(6, 185) = 2.55, p < 0.05; Figure 2B], mean velocity [genotype:
F(3, 183) = 2.27, p = 0.082; interaction: F(6, 183) = 3.32, p <
0.005; Figure 2D], and time spent in fast movements [genotype:
F(3, 185) = 5.17, p < 0.005; interaction: F(6, 185) = 2.73, p < 0.05;
Figure 2E] compared with the three controls, thus reflecting the
occurrence of motor hyperactivity. This was also confirmed by
the reduced resting time exhibited by Syn-Cre/Scn1aWT/A1783V
mice in the computer-aided actimeter [genotype: F(3, 183) = 1.77,
p = 0.154; interaction: F(6, 183) = 3.23, p < 0.005; Figure 2C]
compared with controls. The computer-aided actimeter was also
applied to the same animals when they reached PND40 and
PND60, and, despite the progressive elevation in their values
of ambulation [age: F(2, 185) = 73.6, p < 0.0001; Figure 2A],
frequency of rearing [age: F(2, 185) = 14.5, p< 0.0001; Figure 2B],
mean velocity [age: F(2, 183) = 59.1, p < 0.0001; Figure 2D],
time spent in fast movements [age: F(2, 185) = 60.1, p < 0.0001;
Figure 2E], and their reduction in the resting time [age: F(2, 183)
= 59.8, p < 0.0001; Figure 2C], no changes were evident in
relation with the different genotypes, then indicating that the
hyperactivity was, in general, circumscribed to the pre-adolescent
period (PND25), as also reported in DS patients (Darra et al.,
2019; Verheyen et al., 2019).
Spatial Working Memory
Animals were also subjected to the Y-maze, which serves
as an index of animal abilities in spatial working memory
and spontaneous exploration. Our data at PND25 indicated
a subtle worsening in the performance in this test shown
by Syn-Cre/Scn1aWT/A1783V mice, apparently visible for the
four parameters analyzed (Figures 3A–D). The statistics for
the number of total entries in the arms [genotype: F(3, 148) =
2.13, p = 0.099] and for the % of spontaneous alternation
[genotype: F(3, 148) = 1.80, p = 0.151] confirmed the existence
of numerical trends (toward an increase and toward a decrease,
respectively) for both parameters in Syn-Cre/Scn1aWT/A1783V
mice (Figures 3A,B). However, this did not occur with the
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FIGURE 2 | Evolution of different behavioral parameters recorded in the computer-aided actimeter in Syn-Cre/Scn1aWT/A1783V mice and their three control groups
(Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice) measured at different postnatal days in the range PND25–PND60. Values are means ± SEM of 13–21
animals per group. Data were assessed by using two-way ANOVA for repeated measures followed by the Bonferroni test (*p < 0.05, **p < 0.01, ***p < 0.005 vs. the
other three groups).
FIGURE 3 | Evolution of different behavioral parameters recorded in the Y-maze in Syn-Cre/Scn1aWT/A1783V mice and their three control groups (Scn1aWT/WT,
Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice) measured at different postnatal days in the range PND25–PND60. Values are means ± SEM of 13–21 animals per
group. Data were assessed by using two-way ANOVA for repeated measures followed by the Bonferroni test.
statistics for the % of same arm returns [genotype: F(3, 148) =
1.66, ns] and for the % of alternate arm returns [genotype:
F(3, 148) = 0.94, ns], despite apparently similar increases could
be appreciated in Syn-Cre/Scn1aWT/A1783V mice (Figures 3C,D).
These alterations, as seen with the above behavioral parameters,
disappeared when animals became 40 days old (Figures 3A–D),
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 January 2021 | Volume 13 | Article 602801
Satta et al. Cannabinoids and Dravet Syndrome
although some of the trends were again visible at PND60, for
example, the increase in the % of same arm returns (Figure 3D).
Anxiety
Mice were also examined in the elevated plus maze test, which
provides information on animal anxiety levels. Our data revealed
a lower level in Syn-Cre/Scn1aWT/A1783V mice reflected by a
higher % of time spent in open arms [genotype: F(3, 176) = 4.17,
p < 0.01; interaction: F(6, 176) = 1.56, p = 0.162; Figure 4A]
compared with controls, despite that the number of entries in
these arms was not statistically significant [genotype: F(3, 177) =
2.39, p= 0.07; interaction: F(6, 177) = 1.43, ns; Figure 4B]. Again,
as seen with the above behavioral parameters, these changes
disappeared when animals became 40 days old (Figures 4A,B),
although some differences were again visible at PND60 for both
parameters (Figures 4A,B).
Social Interaction
Syn-Cre/Scn1aWT/A1783V mice were also investigated in a social
interaction test that may reveal potential autistic-like traits, one
of the frequent signs present in DS patients (Skluzacek et al.,
2011; Guerrini, 2012). In this test, Syn-Cre/Scn1aWT/A1783V mice
spent significantly lower time interacting [genotype: F(3, 185) =
26.66, p < 0.0001; Figure 4C], as well as reducing their number
of contacts [genotype: F(3, 185) = 5.042, p < 0.005; Figure 4D],
with a novel unfamiliar partner compared with the other groups,
supporting a deficit in social interaction. Such deficit was found
at PND25 and, contrary to the other behavioral impairments
found at this age in DS mice, it was also found at PND40 and
PND60, as reflecting by the lack of statistical significance for the
age × genotype interaction for both parameters [time in active
interaction: F(6, 185) = 0.504, ns; number of active interactions:
F(6, 185) = 0.472, ns; Figures 4C,D].
Seizuring Activity
Syn-Cre/Scn1aWT/A1783V mice frequently show spontaneous
convulsions (see video in the Supplementary File 2), although
these are difficult to record and quantify. An option to record
the seizuring activity of Syn-Cre/Scn1aWT/A1783V mice is to
determine their vulnerability to proconvulsant agents, so, in
the second experiment, we compared seizuring activity of Syn-
Cre/Scn1aWT/A1783V mice with their controls (only wild-type
mice with no Cre expression: Scn1aWT/WT) once they were
acutely injected with the proconvulsant agent PTZ at PND25.
Our data demonstrated that DS mice responded faster and more
intensely to PTZ compared with controls, as reflected in their
reduction in the latency to myoclonic jerks and generalized
seizures, and the differences between both latencies (trend as
p = 0.058), as well as in the higher time spent in seizures
(Figures 5B–E).
Survival Data
In the first experiment, in which Syn-Cre/Scn1aWT/A1783V
mice and their three controls were recorded between
PND10 and PND60 for detecting possible behavioral
impairment (Figures 1–5), mice were also used for measuring
animal survival. Our data indicated that survival in Syn-
Cre/Scn1aWT/A1783V mice was significantly shorter compared
with the other groups, with almost one of four animals (25%)
dying before PND60 and no death (or only a case) in the
other three genotypes (Figure 5A). It is also important to
remark that, despite the reduction in survival, this exceeded
60 days of life and was significantly much more moderate
compared with the murine model (also based on the A1783V
mutation but expressed in all body cells) used by Ricobaraza
et al. (2019), whose mortality reached up to 75% at similar
ages. This makes our model useful for long-term studies in
this disease, in particular for exploring the comorbidities
associated with DS, which cannot be investigated in models
based on complete deletion of Scn1a gene due to premature
mortality [they die before 2 weeks of age (Ogiwara et al.,
2007)], and can only be partially studied in models based
on heterozygous deletion, which, although present delayed
mortality, reach elevated rates (they die at 3–12 weeks of
age, having only a 20% of long-term survival) at the ages
more adequate for investigating long-term comorbidities
(Yu et al., 2006).
Biochemical and Histopathological Data
In the case of animals of the second experiment (excluding
those used for PTZ injections), they were used to collect
their neural tissues at the PND25, which were used to
analyze some inflammation-related markers in specific
CNS areas whose alteration could be related to behavioral
changes seen during the progression of the pathological
phenotype in Syn-Cre/Scn1aWT/A1783V mice. These
tissues were also used for analyzing the hippocampal
neurogenesis, as well as to determine the status of different
endocannabinoid elements. These data are presented in
Figures 6–11.
Glial Reactivity
Given that the occurrence of glial reactivity and local
neuroinflammatory events in infant epileptic conditions is
well documented (Boer et al., 2010; Iyer et al., 2010; Koh, 2018),
we wanted to investigate whether this happens in our DS mice
at the age at which the behavioral impairment was maximal
(PND25). Our data demonstrated elevated glial reactivity,
reflected in both higher GFAP (Figure 6) and Iba-1 (Figure 7)
immunoreactivity and also in morphological changes (shift
to an activated state) in GFAP- or Iba-1-positive cells, in
the prefrontal cortex (Figures 6A, 7A) and the hippocampal
dentate gyrus (Figures 6B, 7B) of Syn-Cre/Scn1aWT/A1783V
mice compared with controls. By contrast, such astrogliosis and
microgliosis were not found in the different subfields (CA1,
CA2, and CA3) of the hippocampal Ammon’s horn or in the
striatum (Figures 6C–F, 7C–F). In parallel, we also measured
gene expression of the proinflammatory cytokine TNF-α,
which was apparently elevated in different CNS structures of
Syn-Cre/Scn1aWT/A1783V mice, in particular in the hippocampus
(p = 0.065), although these differences did not reach statistical
significance in any case, likely due to a high variation in these
mice (Figure 8A). It is important to remark that for these
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FIGURE 4 | Evolution of different behavioral parameters recorded in the elevated plus maze (upper panels) and in the social interaction test (lower panels) in
Syn-Cre/Scn1aWT/A1783V mice and their three control groups (Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice) measured at different postnatal days in
the range PND25–PND60. Values are means ± SEM of 11–21 animals per group. Data were assessed by using two-way ANOVA for repeated measures followed by
the Bonferroni test (*p < 0.05, **p < 0.01, ***p < 0.005 vs. control groups; #p < 0.05 vs. Scn1aWT/WT group).
FIGURE 5 | Animal survival in Syn-Cre/Scn1aWT/A1783V mice and their three control groups (Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice), and
seizuring activity in Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals after an acute injection of PTZ at PND25 (lower panels). Values are means ±
SEM of six to eight animals per group. Data were assessed by Kaplan-Meier analysis (survival data) and by the Student’s t-test (PTZ experiment; *p < 0.05, **p < 0.01
vs. the control group).
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FIGURE 6 | Immunoreactivity for the astroglial marker GFAP measured by immunofluorescence in different CNS structures, including representative
immunofluorescence images in the prefrontal cortex and the hippocampal dentate gyrus of Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals at
PND25. Values are % over controls and correspond to means ± SEM of five to six animals per group. Data were assessed by the Student’s t-test (*p < 0.05, **p <
0.01 vs. the control group). Scale bar = 100µm.
data, only tissues from Syn-Cre/Scn1aWT/A1783V mice and the
control animals having expression of a wild-type SCN1A gene
and no Cre recombinase expression (Scn1aWT/WT mice) were
analyzed. We excluded the analyses of the other two control
genotypes (Syn-Cre/Scn1aWT/WT and Scn1aWT/A1783V mice)
given that no differences among the three control genotypes were
found in the behavioral recording. To confirm this fact also in the
neuropathological data, we carried out a few analyses using GFAP
and Iba-1 immunofluorescence in the three control genotypes,
whose results (similar in the three genotypes) are shown in the
Supplementary File 3.
Neurogenesis Dysregulation
Epilepsy has also been associated with alterations in hippocampal
neurogenesis in the dentate gyrus (Bielefeld et al., 2019; Chen
et al., 2020), and this was also investigated in our Syn-
Cre/Scn1aWT/A1783V mice. We found a higher granule cell
dispersion (Figure 9A) and a trend toward an increase (p= 0.13)
in the number of positive cells for Ki67, a marker of proliferating
cells (Figure 9B), supporting the idea of an elevated mobilization
of progenitor cells in Syn-Cre/Scn1aWT/A1783V mice. Using
double-labeling analyses with Ki67 and GFAP in the GCL and
the SGZ (Figure 9C), we found that the number of positive cells
for both markers was higher in Syn-Cre/Scn1aWT/A1783V mice
[both as total (p < 0.01) and as % (trend: p = 0.106)] compared
with Scn1aWT/WT mice (Figures 9D,E). Cell proliferation was
mostly restricted to the SGZ, and in other models of epilepsy,
including mesial temporal lobe epilepsy (MTLE) (Sierra et al.,
2015) and other inducible model of DS (Martín-Suárez et al.,
2020), neural stem cells (NSCs) rather than astrocytes have
been found to proliferate in higher number (Sierra et al., 2015;
Martín-Suárez et al., 2020). This alteration correlates with a
phenotypical change consisting in the transformation into a
reactive-like phenotype of NSCs which can also be observed
in our model (Figure 9C). Because of the agreements with
previous reports, we interpret these data as indicating a reactive
neurogenic response likely participating to reactive gliogenesis
(Sierra et al., 2015; Martín-Suárez et al., 2020). We also found
that neurons forming the GCL had altered nuclear morphology
in the DS mice. Instead of the typical round nuclei of the
normal mice, in the DS, nuclei presented an irregular contour
with indentations. The measurement of nuclei circularity showed
a significant decrease in the DS mice (Figures 9F,G). The
cause of this morphological transformation remains unknown,
but it has been related to cell damage as it is found in
different pathologies.
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FIGURE 7 | Immunoreactivity for the microglial marker Iba-1 measured by immunofluorescence in different CNS structures, including representative
immunofluorescence images in the prefrontal cortex and the hippocampal dentate gyrus, of Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals at
PND25. Values are % over controls and correspond to means ± SEM of five to six animals per group. Data were assessed by the Student’s t-test (*p < 0.05, **p <
0.01 vs. the control group). Scale bar = 100µm.
FIGURE 8 | Gene expression for TNF-α and BDNF measured by qPCR in different CNS structures of Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W
animals at PND25. Values are fold of change over controls and correspond to means ± SEM of five to six animals per group. Data were assessed by the Student’s
t-test.
BDNF gene expression was also measured in the
hippocampus and also in other CNS structures (prefrontal
cortex, striatum, and cerebellum), but no differences between
Syn-Cre/Scn1aWT/A1783V mice and controls were detected, with
the only exception of a trend toward a decrease seen in the
prefrontal cortex (Figure 8B).
Endocannabinoid Dysregulation
As mentioned above, neural tissues collected in the second
experiment were also used for determining the status of different
elements of the endocannabinoid signaling, which may serve as
potential targets for a cannabinoid-based therapy in DS (Rubio
et al., 2016; Gray and Whalley, 2020). The objective of these
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FIGURE 9 | Double immunofluorescence analysis of Ki67 and GFAP in the hippocampal dentate gyrus, including representative immunofluorescence images, of
Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals at PND25. Values are means ± SEM of six animals per group. Data were assessed by the
Student’s t-test (*p < 0.05, **p < 0.01 vs. the control group). Scale bar for double labeling = 50µm (top panels) and 20µm (bottom panels).
analyses was to detect a possible dysregulation in this signaling
system in different CNS structures of Syn-Cre/Scn1aWT/A1783V
mice, following previous data described in lymphocytes of DS
patients (Rubio et al., 2016), which may explain the expected
efficacy of cannabinoids as disease modifiers in DS. Our data
confirmed this possible dysregulation although this would
be restricted to specific CNS structures. Thus, our qPCR
analysis demonstrated that the CB1 receptor was downregulated
in the cerebellum, with a small trend toward a decrease in
the hippocampus (p = 0.179) of Syn-Cre/Scn1aWT/A1783V
mice (Figure 10A), which was corroborated by western
blot analysis (Figure 11E). No changes were found in the
prefrontal cortex and the striatum (Figures 10A, 11A). With
regard to the CB2 receptor, we did not find any changes
with qPCR in the different structures analyzed in Syn-
Cre/Scn1aWT/A1783V mice (Figure 10B), whereas we found
elevated CB2 receptor levels measured by western blot in the
hippocampus (Figure 11F) but not in the prefrontal cortex
(Figure 11B). We also analyzed the orphan GPR55 receptor,
which was proposed as the target for the benefits of CBD
against seizures and autistic signs in the study by Kaplan et al.
(2017) conducted in an experimental model of DS. Using
qPCR analysis, we detected some trends toward a decrease
in the striatum (p = 0.2), hippocampus (p = 0.15), and
cerebellum (p = 0.34) of Syn-Cre/Scn1aWT/A1783V mice, which
did not reach statistical significance due to high variability,
in particular in Scn1aWT/WT mice (Figure 10C). With regard
to the endocannabinoid-inactivating enzymes, we found a
reduction in MAGL-mRNA in the cerebellum and prefrontal
cortex of Syn-Cre/Scn1aWT/A1783V mice, which was confirmed
at the protein level only in the case of the prefrontal cortex
(Figure 11D). We did not found any changes in the striatum,
measured by qPCR (Figure 10G), and in the hippocampus,
measured by qPCR (Figure 10G) and western blot (Figure 11H).
The other major endocannabinoid-inactivating enzyme, FAAH,
was not modified in the prefrontal cortex (Figures 10F, 11C)
and the striatum (Figure 10F) of Syn-Cre/Scn1aWT/A1783V
mice, although a trend toward a decrease in the qPCR analysis
could be appreciated in the cerebellum (p = 0.068) and the
hippocampus (p = 0.062) (Figure 10F), in this last case also
found with the western blot analysis (p = 0.057) (Figure 11G).
Lastly, the expression of the enzymes that synthesize
endocannabinoids, NAPE-PLD and DAGL, was not found
to be altered in Syn-Cre/Scn1aWT/A1783V mice (Figures 10D,E).
Representative blots of all proteins analyzed are shown in the
Supplementary File 4.
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FIGURE 10 | Gene expression for the CB1, CB2, and GPR55 receptors and the NAPE-PLD, DAGL, FAAH, and MAGL enzymes measured by qPCR in different CNS
structures of Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals at PND25. Values are fold of change over controls and correspond to means ± SEM
of five to six animals per group. Data were assessed by the Student’s t-test (*p < 0.05, **p < 0.01 vs. the control group).
DISCUSSION
As indicated and justified in the “Introduction,” our study has
been conducted with heterozygous conditional knock-in mice
carrying a missense mutation (A1783V) in Scn1a gene, which
were crossed with mice expressing Cre-recombinase linked to
synapsin-1 promoter, then generating Syn-Cre/Scn1aWT/A1783V
mice bearing the A1783V mutation in Nav1.1 protein expressed
exclusively in CNS neurons. Our first objective was to
demonstrate that they recapitulate most of the cardinal
neurological signs seen in DS patients, including the long-
term comorbidities. Our data confirmed that these animals
showed cerebral hyperexcitability manifested by spontaneous
seizures and, more specifically, by a greater sensitivity to the
proconvulsant agent PTZ, showing, in particular, a lower latency
to seizuring, as also found in other DS models (Ogiwara
et al., 2007; Tai et al., 2014). Our animals also presented some
important DS comorbidities, also found in other DS models
(Cheah et al., 2012; Han et al., 2012; Tatsukawa et al., 2018;
Stein et al., 2019), as hyperactivity (with no changes in motor
coordination), a subtle memory impairment, apparently less
anxiety, and, in particular, an altered social behavior reflecting
possibly the occurrence of autistic traits. All these behavioral
signs, which represent some important features present in
patients (Skluzacek et al., 2011; Guerrini, 2012; Darra et al.,
2019), were found in Syn-Cre/Scn1aWT/A1783V mice at PND25,
although we assume that they may be present at earlier ages at
which the performance of these tests is not possible due to animal
immaturity. This assumption is based on the detection of changes
in hindlimb grasp reflexes at PND10, which likely indicates that
these mice apparently have a delayed motor development as
shown to occur in patients (Verheyen et al., 2019). We also
investigated the mortality in our mice. As mentioned above,
models based on the homozygous (Ogiwara et al., 2007) and
heterozygous [only 20% of long-term survival (Yu et al., 2006)]
deletion of Scn1a gene have been associated with high mortality,
in particular when the gene deletionwas complete and carried out
inmice with the C57BL/6 background, which results in extremely
premature death [around 2 weeks after birth (Ogiwara et al.,
2007)]. Models based on the widespread A1783Vmutation of the
Nav1.1 channel also reduce the survival of animals from PND20
reaching up to 75% at PND40 (Ricobaraza et al., 2019), and
this also happens when the mutation is expressed exclusively in
GABAergic neurons [100% of mice died prior to PND25 (Kuo
et al., 2019)], making it difficult to extend the period under
investigation to juvenile and adult ages. Interestingly, when the
mutation of the channel is not exclusive of GABAergic neurons,
but expressed in different CNS neurons, as is the case in our
model, the survival reaches up to 75% of the animals after the
PND20 remaining unaltered up to PND60. This higher survival
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FIGURE 11 | Protein levels for the CB1 and CB2 receptors and the FAAH and MAGL enzymes measured by western blot in the prefrontal cortex and the
hippocampus of Syn-Cre/Scn1aWT/A1783V mice compared with Scn1aWT/W animals at PND25. Values are % over controls and correspond to means ± SEM of five to
six animals per group. Data were assessed by the Student’s t-test (*p < 0.05 vs. the control group).
of our animals facilitates to confirm the persistence in these
animals of some of the comorbidities found at PND25, in our
case, in particular the autistic traits seen in the social interaction
test, which still persist at PND40 and PND60, and also some
signs detected in the elevated plus maze test, which disappeared
at PND40 but were again visible at PND60. By contrast, signs
as hyperactivity were only visible at PND25 disappearing in the
following ages investigated.
Our second objective in this study was to explore the
neuropathological alterations associated in CNS structures
with these behavioral anomalies. We concentrated the
study in PND25, which was the most affected age in Syn-
Cre/Scn1aWT/A1783V mice and paid emphasis on local
inflammatory events in view of the contribution that these
events appear to have in the DS pathogenesis as indicated in
recent studies (Boer et al., 2010; Iyer et al., 2010; Koh, 2018).
Our data confirmed two CNS structures significantly altered,
the prefrontal cortex and the hippocampal dentate gyrus, which
may explain the emotional and memory impairments detected
in the behavioral tests, but not in other areas such as the striatum
despite the changes found in motor activity. In these two areas,
we detected elevated reactive astrogliosis (labeled with GFAP)
and microgliosis (labeled with Iba-1), associated, in the case of
the hippocampus, with elevated levels of TNF-α mRNA levels,
which support the occurrence of local inflammatory events that
may be, in part, responsible of the long-term deficits observed
in the disease. Hippocampal postnatal and adult neurogenesis
is greatly modified by seizures (Bielefeld et al., 2019; Chen
et al., 2020). We investigated in particular the response of
hippocampal NSCs in the dentate gyrus, as reports from the last
years show how this normally neurogenic cell type transforms
into a reactive phenotype (reactive NSCs) with abnormal
morphology and increased mitotic activity that contributes
to reactive gliogenesis (Sierra et al., 2015; Muro-García et al.,
2019). These alterations have also been reported very recently
to take place in other murine models of DS (Martín-Suárez
et al., 2020) and could be potentially responsible, at least in
part, of cognitive deficits associated with these conditions. In
our study, we detected a trend toward elevated cell proliferation
in Syn-Cre/Scn1aWT/A1783V mice, which corresponded more
to cell division of GFAP-positive cells rather than to neurons.
We hypothesize that these are NSCs rather than astrocytes
as this cell type was not found to enter cell division in the
studies mentioned above and cell proliferation was restricted
to the SGZ and GCL in our work. As normally NSCs account
for a small proportion of dividing cells in the dentate gyrus,
a significant increase in NSC activation is compatible with a
comparatively smaller increment in overall cell division. The
data presented herein suggest that, in our model, NSCs could
also contribute to reactive astrogliosis found in the hippocampal
dentate gyrus which might be at the expense of neurogenesis in
Syn-Cre/Scn1aWT/A1783V mice as a direct response to seizures.
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Alternatively, the response of the hippocampal dentate gyrus
in our mice could be secondary and attributed to the extreme
inflammatory events and glial reactivity generated by the highly
seizuring activity occurring in these mice. Further studies
centered in hippocampal neurogenesis will help to clarify these
points. Related to gliosis in the dentate gyrus, we found also
granule cell dispersion, normally found in focal epilepsies such
as MTLE (Sierra et al., 2015; Muro-García et al., 2019). Finally,
we found abnormal morphology of the nuclei of neurons in the
GCL whose cause is still unknown but have been proposed to be
associated with altered lamin expression (Goldman et al., 2004;
Vergnes et al., 2004).
As mentioned in the “Introduction,” cannabinoids, in
particular CBD, have recently been proposed as potential
antiseizuring agents in DS and other similar infantile syndromes
based on successful clinical trials conducted with Epidiolex R©
(pure CBD) in children affected by these syndromes (Devinsky
et al., 2016, 2018; Nabbout and Thiele, 2020). We have
also indicated in the “Introduction” that CBD (and other
cannabinoids too) may have additional therapeutic properties
of interest for the different comorbidities occurring in these
syndromes, given its anti-inflammatory, antioxidant and, in
general, cytoprotective properties, all of them well-demonstrated
during years in adult individuals (Hill et al., 2012; Fernández-
Ruiz et al., 2013) and also in the pediatric field against
neonatal hypoxia-ischemia and other disorders related to
neurodevelopment (Sagredo et al., 2018). This potential has
already been investigated in a couple of previous studies
(Kaplan et al., 2017; Patra et al., 2020), which demonstrated
in animal models of DS the efficacy of CBD in preventing
premature mortality and in improving some associated
comorbidities (anxiety, depression, autism, motor impairment,
and memory defects). In this context, we addressed as a
third objective in our current study to explore the status of
the endocannabinoid signaling in specific CNS structures of
Syn-Cre/Scn1aWT/A1783V mice, in particular those areas more
related to comorbidities found in these mice. Our hypothesis
is that the endocannabinoid signaling may be dysregulated in
DS and that CBD (and other cannabinoids) may be active in
correcting such dysregulation, following the data obtained in
studies in other neurological disorders (Cristino et al., 2020).
In fact, the idea of an endocannabinoid dysregulation in DS
was previously investigated in our laboratory in a clinical study
consisting in the analysis of lymphocytes isolated from patients
(Rubio et al., 2016). We analyzed different components of the
endocannabinoid system, intracellular signals down-stream the
endocannabinoid-related receptors, and also some potential
targets for CBD that are outside the endocannabinoid signaling.
Our data revealed a significant increase in CB2 receptors, an
important element of the endocannabinoid system that has
been related to inflammatory responses (Fernández-Ruiz et al.,
2007), which was paralleled by increases in some cytokines
(e.g., TNF-α, IL-1β), in the PPAR-γ nuclear receptor, and
in the marker of lymphocyte activation Cd70 (Rubio et al.,
2016), supporting the idea that inflammation could have an
important influence in DS pathogenesis and, in general, in
drug-resistant infantile epilepsies (Boer et al., 2010; Iyer
et al., 2010; Koh, 2018). Similar data (upregulation in the
CB2 receptor) have been found in the postmortem brain
of epileptogenic developmental pathologies (Zurolo et al.,
2010) and also in peripheral blood mononuclear cells of
children affected by autistic disorders (Siniscalco et al.,
2013). Our present study confirmed the relevance of this
response, as we found elevated levels of the CB2 receptor
in the hippocampus (one of the areas in our study, in
particular, the dentate gyrus, that was most affected by glial
reactivity), although not in other CNS structures, in Syn-
Cre/Scn1aWT/A1783V mice. It is possible that this upregulation
of the CB2 receptor found in the hippocampus means an
endogenous protective response aimed at controlling the
inflammatory response in DS, as has been found to occur
in other neurological disorders (Fernández-Ruiz, 2019), but
this would require further research aimed at identifying the
neural substrates within the hippocampus where the elevation
of CB2 receptors take place, as well as to confirm the benefits
of compounds targeting this receptor in the control of local
inflammatory responses.
The upregulation of the CB2 receptor was not the only
response of the endocannabinoid system found in Syn-
Cre/Scn1aWT/A1783V mice. We also found that the CB1
receptor was possibly downregulated in the cerebellum and
the hippocampus, supporting the idea of an impairment in
the synaptic function played by this receptor by modulating
transmitter release in excitatory and inhibitory neurons of
both structures, which could be compatible with the motor
and memory changes found in these mice. Reductions in
the endocannabinoid inactivating enzymes, were also evident
in the cerebellum (both MAGL and FAAH), the prefrontal
cortex (only MAGL), and the hippocampus (only FAAH) of
Syn-Cre/Scn1aWT/A1783V mice, supporting a possible elevation
in endocannabinoid levels, in particular 2-AG given that
changes in MAGL in Syn-Cre/Scn1aWT/A1783V mice appear to
be stronger. Such elevation would need to be confirmed in
further studies but may be compatible with the endogenous
protective responses exerted by 2-AG in conditions of brain
damage, as shown to occur in chronic neurodegenerative diseases
(Xu and Chen, 2015) or in brain trauma (Panikashvili et al.,
2001).
In conclusion, Syn-Cre/Scn1aWT/A1783V mice exhibited
spontaneous convulsions and a greater responsiveness when
seizures were induced with PTZ at PND25, accompanied by
hyperactivity, certain memory impairment, less anxiety, and an
altered social behavior, which represent some important features
present in humans. These alterations tended to disappear at
days after PND25, with the only exception of altered social
interaction, which still persists at PND60, and, in part, lower
anxiety. These behavioral impairments were associated with
greater glial reactivity and generation of reactive NSCs in the
hippocampal neurogenic niche, as well as with changes in some
endocannabinoid receptors and enzymes that would support the
idea of a possible endocannabinoid dysregulation restricted to
specific CNS structures.
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Supplementary File 2 | Video recording of spontaneous seizures shown by one
Syn-Cre/Scn1aWT/A1783V mouse.
Supplementary File 3 | Comparison of the immunoreactivity for the astroglial
marker GFAP and the microglial marker Iba-1, measured by immunofluorescence
in the prefrontal cortex and the hippocampal dentate gyrus, among the three
control groups (Scn1aWT/WT, Syn-Cre/Scn1aWT/WT, and Scn1aWT/A1783V mice) for
Syn-Cre/Scn1aWT/A1783V mice at the PND25. Values are means ± SEM of more
than six animals per group. Data were assessed by using one-way ANOVA
followed by the Bonferroni test (GFAP: prefrontal cortex: F (2, 17) = 1.458, ns;
hippocampal dentate gyrus: F (2, 17) = 1.094, ns; Iba-1: prefrontal cortex: F (2, 17) =
0.076, ns; hippocampal dentate gyrus: F (2 17) = 0.203, ns).
Supplementary File 4 | Representative blots corresponding to the analysis of
protein levels for the CB1 and CB2 receptors and the FAAH and MAGL enzymes
in the prefrontal cortex and the hippocampus of Syn-Cre/Scn1aWT/A1783V mice
compared with Scn1aWT/W animals at PND25. As indicated in the “Materials and
Methods” section, images were analyzed with Image Lab software (Bio-Rad
Laboratories, CA, USA) to generate the quantitative data presented in Figure 11,
which corresponded to mean ± SEM of values of the ratio between the optical
densities of the specific protein (CB1, CB2, FAAH, MAGL) band and the total
protein (escalated according to molecular weights) measured in membranes for
each sample. As indicated in the legend to Figure 11, the two experimental
groups consisted of five to six different individual data each coming from a
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